Analytical Data
-
Gene name
MLKLAK
- Application
-
Alternative Names
AZK; Cervical cancer suppressor gene 4 protein; HCCS 4; HCCS-4; HCCS4; Human cervical cancer suppressor gene 4 protein; Leucine zipper and sterile alpha motif containing kinase; Leucine zipper- and sterile alpha motif-containing kinase; Mitogen activated protein kinase kinase kinase MLT; Mitogen-activated protein kinase kinase kinase MLT; Mixed lineage kinase 7; Mixed lineage kinase related kinase; Mixed lineage kinase related kinase MRK beta; Mixed lineage kinase with a leucine zipper and a sterile alpha motif; Mixed lineage kinase-related kinase; MLK 7; MLK like mitogen activated protein triple kinase; MLK related kinase; MLK-like mitogen-activated protein triple kinase; MLK-related kinase; MLK7; Mlklak; MLT; MLTK_HUMAN; MRK; Sterile alpha motif and leucine zipper containing kinase AZK; Sterile alpha motif- and leucine zipper-containing kinase AZK; Zak
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NYL2
-
Expression Region
1-800 aa
-
AA Sequence
MSSLGASFVQ IKFDDLQFFE NCGGGSFGSV YRAKWISQDK EVAVKKLLKI EKEAEILSVL SHRNIIQFYG VILEPPNYGI VTEYASLGSL YDYINSNRSE EMDMDHIMTW ATDVAKGMHY LHMEAPVKVI HRDLKSRNVV IAADGVLKIC DFGASRFHNH TTHMSLVGTF PWMAPEVIQS LPVSETCDTY SYGVVLWEML TREVPFKGLE GLQVAWLVVE KNERLTIPSS CPRSFAELLH QCWEADAKKR PSFKQIISIL ESMSNDTSLP DKCNSFLHNK AEWRCEIEAT LERLKKLERD LSFKEQELKE RERRLKMWEQ KLTEQSNTPL LPSFEIGAWT EDDVYCWVQQ LVRKGDSSAE MSVYASLFKE NNITGKRLLL LEEEDLKDMG IVSKGHIIHF KSAIEKLTHD YINLFHFPPL IKDSGGEPEE NEEKIVNLEL VFGFHLKPGT GPQDCKWKMY MEMDGDEIAI TYIKDVTFNT NLPDAEILKM TKPPFVMEKW IVGIAKSQTV ECTVTYESDV RTPKSTKHVH SIQWSRTKPQ DEVKAVQLAI QTLFTNSDGN PGSRSDSSAD CQWLDTLRMR QIASNTSLQR SQSNPILGSP FFSHFDGQDS YAAAVRRPQV PIKYQQITPV NQSRSSSPTQ YGLTKNFSSL HLNSRDSGFS SGNTDTSSER GRYSDRSRNK YGRGSISLNS SPRGRYSGKS QHSTPSRGRY PGKFYRVSQS ALNPHQSPDF KRSPRDLHQP NTIPGMPLHP ETDSRASEED SKVSEGGWTK VEYRKKPHRP SPAKTNKERA RGDHRGWRNF
-
Molecular Weight
91.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MLKLAK, a fusion protein derived from the nucleotide-binding domain of the MLR (multi-lysine response) protein and the leucine zipper domain of the LAK (lymphokine-activated killer) protein, has garnered increasing attention in the field of molecular biology and therapeutic development. The MLKLAK protein has been studied for its potential application in immunotherapy, particularly in enhancing the anti-tumor activity of immune cells. Research indicates that modifying and optimizing MLKLAK can improve its stability and efficiency in promoting T-cell activation and proliferation. The protein's unique structural features allow it to interact effectively with specific receptors on immune cells, thereby facilitating targeted immune responses. Moreover, understanding its mechanisms of action provides insights into the broader context of cancer immunology and the design of novel therapeutic strategies. With the rising prevalence of various cancers and the limitations of conventional treatments, MLKLAK represents a promising avenue for developing new, more effective immunotherapeutic options. Ongoing studies aim to elucidate its interaction pathways and optimize its characteristics to maximize its therapeutic potential while minimizing adverse effects, paving the way for future clinical applications.
